WallStSmart

Gauzy Ltd. Ordinary Shares (GAUZ)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Zepp Health Corp generates 167% more annual revenue ($258.90M vs $96.81M). ZEPP leads profitability with a -15.5% profit margin vs -39.6%. ZEPP earns a higher WallStSmart Score of 41/100 (D).

GAUZ

Avoid

32

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 5.0Quality: 3.5
Piotroski: 7/9Altman Z: -2.22

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for GAUZ.

ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GAUZ1 strengths · Avg: 10.0/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

GAUZ4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$12.93M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-94.5%2/10

ROE of -94.5% — below average capital efficiency

Revenue GrowthGrowth
-17.8%2/10

Revenue declined 17.8%

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : GAUZ

The strongest argument for GAUZ centers on Price/Book.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : GAUZ

The primary concerns for GAUZ are EPS Growth, Market Cap, Return on Equity. Debt-to-equity of 3.54 is elevated, increasing financial risk.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

GAUZ profiles as a turnaround stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor ELECTRONIC COMPONENTS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ZEPP scores higher overall (41/100 vs 32/100) and 43.0% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Gauzy Ltd. Ordinary Shares

TECHNOLOGY · ELECTRONIC COMPONENTS · USA

Gauzy Ltd. (Ticker: GAUZ) is an innovative technology leader in advanced glass solutions, leveraging proprietary electrochromic and Suspended Particle Device (SPD) technologies to enhance energy efficiency, user comfort, and design aesthetics across the automotive and architectural industries. With a robust portfolio of partnerships and a strong commitment to sustainability, Gauzy is well-positioned to meet the increasing global demand for intelligent building materials and automotive advancements. The company’s cutting-edge smart glass applications are set to redefine both commercial and residential spaces, establishing Gauzy as a critical player in the rapidly evolving market for smart design solutions.

Visit Website →

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?